Chengd Pharmaceutical (301201.SZ): Some fundraising projects have been completed.

On January 3, Gelonghui reported that Chengda Pharmaceutical Co., Ltd. (301201.SZ) announced that recently, the fundraising investment projects "Pharmaceutical Intermediate Project" and "Active Pharmaceutical Ingredient Project" have been completed and reached the designated usable status, meeting the project completion conditions. Therefore, the company has decided to conclude the "Pharmaceutical Intermediate Project" and "Active Pharmaceutical Ingredient Project."

Gelonghui FinanceJan 3 16:00

Express News | Chengda Pharmaceutical: Completion of pharmaceutical intermediates project and Active Pharmaceutical Ingredient project.

BreakingsJan 3 15:59

Express News | Chengda Pharmaceutical: Re-certified as a high-tech enterprise.

BreakingsJan 3 15:57

Chengda Pharmaceutical (301201.SZ): Active Pharmaceutical Ingredients such as Edaravone Sodium and Rivaroxaban are currently under registration application.

On December 17, Gelonghui reported that Chengda Pharmaceutical (301201.SZ) stated in a recent investor relations activity that the Active Pharmaceutical Ingredient L-carnitine has been approved by the regulatory authorities of several countries and obtained the CEP certification in Europe, covering quality system certification for major global markets. The Active Pharmaceutical Ingredient Brinfido has been approved by South Korea's MFDS, while the Active Pharmaceutical Ingredients Aflibercept and Rivaroxaban are in the process of registration. The Active Pharmaceutical Ingredient Daglizhuo passed CDE approval in November 2024, further enriching the company's product line.

Gelonghui FinanceDec 17, 2024 17:52

Express News | Overview of Share Buyback in A-shares: 16 companies disclose buyback progress.

BreakingsDec 12, 2024 07:32

Chengda Pharmaceutical (301201.SZ): The L-carnitine series products are exported to over 30 global countries, with stable quality.

On December 9, Gelonghui reported that Chengda Pharmaceutical (301201.SZ) recently stated in an investor relations activity that the company's L-carnitine series products are exported to over 30 countries globally, with stable quality and a good international reputation, making it one of the main suppliers of L-carnitine worldwide. Currently, the sales prices of the company's L-carnitine products are relatively stable, having slightly improved from the lowest market prices, but there remains a certain level of uncertainty regarding the future price trend of related products.

Gelonghui FinanceDec 9, 2024 18:07